Vietnam Genetic Market

The Vietnam Genetic Market was estimated at USD 112 Mn in 2025. The estimate covers commercial clinical genetic-testing services, directly attributable assays and consumables, clinical bioinformatics, and interpretation revenue earned in Vietnam. It excludes agricultural genetics, forensic testing, gene-therapy products, non-commercial academic grants, and export revenue not generated through Vietnam-based operations. Prenatal and newborn screening represented the largest service category, while Ho Chi Minh City and Hanoi together accounted for most commercial demand and advanced laboratory capacity.

The market is projected to reach USD 243 Mn by 2031, expanding at a 13.8% CAGR from the 2025 base. Annual commercial test volumes are forecast to reach approximately 1.55 million, compared with 610,000 in 2025. Growth should remain strongest in oncology, rare disease sequencing, liquid biopsy, hereditary panels, and carrier screening. Average revenue per test is expected to decline as routine panels become more affordable, but the mix shift toward clinically complex NGS services will preserve double-digit value growth.

Profit pools will move away from basic sample collection and undifferentiated testing toward proprietary assays, oncology biomarkers, liquid biopsy, bioinformatics, clinical interpretation, and physician-integrated decision support. NGS-based services are projected to increase from 45% of market revenue in 2025 to 66% in 2031. Routine NIPT and relationship-testing margins will compress as capacity expands, while providers with proprietary algorithms, local variant databases, counseling capabilities, and recurring cancer-monitoring workflows should retain stronger pricing power and customer relationships.

Affordability remains the broadest commercial constraint, while data governance is the fastest-rising operating constraint. Advanced genetic tests are still predominantly self-funded and concentrated in large cities. At the same time, Vietnam's Personal Data Protection Law and Decree 356 classify genetic characteristics as sensitive personal data and impose requirements covering impact assessments, security, consent, and cross-border transfers. Laboratories must therefore reduce unit costs without weakening security, clinical quality, or compliance, which increases the minimum efficient operating scale.

Vietnam ranks below Singapore, Thailand, and Malaysia in 2025 market value among the selected peers, but its forecast growth is faster than all three. Vietnam's 13.8% CAGR compares with 10.2% for Singapore, 11.1% for Thailand, and 11.8% for Malaysia. Indonesia is forecast to grow slightly faster at 14.6%. Vietnam benefits from a large population, a substantial birth cohort, an emerging local testing industry, and biotechnology-localization policy, but remains behind regional leaders in national genomic-database scale.

Prenatal and newborn screening provides the largest near-term volume pool because Vietnam records about 1.48 million births annually and more than 40,000 newborns are affected by congenital conditions. Oncology testing provides the strongest value-growth opportunity because Vietnam recorded 177,404 new cancer cases in 2024 and more than 404,000 five-year prevalent cases. Together, these applications support both high-throughput screening and higher-value diagnostic, therapy-selection, and monitoring services across private and public care settings.

Winning providers need clinically validated assays, efficient sample logistics, physician education, specialist interpretation, genetic counseling, secure data systems, and reliable turnaround times. Laboratories also require sufficient test volume to utilize sequencing capacity economically and fund quality assurance. Local reference data are increasingly important because population-specific variants may be misclassified using predominantly non-Asian databases. Commercial leaders should integrate testing with hospital workflows and develop proprietary oncology, reproductive-health, or rare-disease capabilities rather than relying entirely on imported commodity panels.